

2031249PC.ST25.txt
SEQUENCE LISTING

<110> Karyon Oy Ab
<120> Tumor targeting agents and uses thereof
<130> 2031249PC
<150> FI 20021761
<151> 2002-10-03
<160> 7
<170> PatentIn version 3.2
<210> 1
<211> 5
<212> PRT
<213> Artificial
<220>
<223> synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(5)
<223> cysteine bridge

<400> 1

Cys Leu Arg Ser Cys
1 5

<210> 2
<211> 5
<212> PRT
<213> Artificial

<220>
<223> synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(5)
<223> cysteine bridge

<400> 2

Cys Ser Arg Leu Cys
1 5

<210> 3
<211> 5
<212> PRT
<213> Artificial

<220>
<223> synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(5)
<223> lactam bridge

<400> 3

Asp Leu Arg Ser Lys
1 5

<210> 4
<211> 7
<212> PRT
<213> Artificial

<220>
<223> synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(7)
<223> lactam bridge

<400> 4

Asp Leu Arg Ser Gly Arg Lys
1 5

<210> 5
<211> 7
<212> PRT
<213> Artificial

<220>
<223> synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(7)
<223> lactam bridge

<400> 5

Asp Arg Gly Leu Arg Ser Lys
1 5

<210> 6
<211> 5
<212> PRT
<213> Artificial

<220>
<223> synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(5)
<223> amide bond

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Ornithine

<400> 6

Xaa Leu Arg Ser Glu
1 5

<210> 7
<211> 5
<212> PRT
<213> Artificial

<220>
<223> synthetic

<220>
<221> MISC_FEATURE
<222> (1)..(5)
<223> lactam bridge

<400> 7

Lys Leu Arg Ser Asp
1 5